Chronoscale Holdings Corp quarterly report, Q2 FY2017

Filing summary: Ekso Bionics Holdings, Inc. (Form 10-Q)

Entity note: The supplied filing is for Ekso Bionics Holdings, Inc. (Nasdaq: EKSO), not Chronoscale Holdings Corp. It covers the quarter and six months ended June 30, 2017; financial statements are unaudited. Amounts below are in millions of dollars unless noted.

Business context and reporting period

Ekso develops and sells exoskeletons for medical rehabilitation and industrial applications, and also provides engineering services. Management said the company was in an early commercialization stage. Its stated focus was commercializing the Ekso GT rehabilitation device and industrial products, while pursuing clinical, product-development and sales initiatives.

Financial performance and liquidity

MetricQ2 2017Q2 2016Six months 2017Six months 2016
Revenue$1.867$1.552$3.303$10.038
Gross profit$0.396$0.203$0.748$1.701
Gross margin21.2%13.1%22.6%16.9%
Operating loss$(8.459)$(7.396)$(16.600)$(14.038)
Net loss$(5.507)$(5.765)$(13.809)$(9.416)
Net loss per share$(0.22)$(0.61)$(0.58)$(1.06)
  • Q2 revenue rose 20%, led mainly by industrial device sales; device and related revenue increased 29%. There was no engineering-services revenue in Q2 2017.
  • First-half revenue fell 67%. Management attributed most of the decline to $6.5 million of previously deferred medical-device revenue recognized in the first half of 2016 under a change in revenue-recognition estimates; 2016 also included $0.5 million of engineering-services revenue.
  • Q2 operating expenses were $8.855 million, including $0.665 million of restructuring costs. First-half operating expenses were $17.348 million, up 10% year over year.
  • Net loss included noncash gains from revaluing warrant liabilities: $3.106 million in Q2 and $3.037 million in the first half of 2017. These gains depend substantially on the company’s share price.
  • Cash was $10.701 million at June 30, down from $16.846 million at year-end 2016. Operating cash use was $16.859 million in the first half; investing cash use was $0.248 million. Financing provided $10.923 million, primarily from the April equity offering.
  • Working capital was $8.714 million, based on current assets of $15.301 million less current liabilities of $6.587 million. Stockholders’ equity was $1.628 million, and accumulated deficit was $128.841 million.
  • Debt carrying value was $6.878 million, including $0.972 million classified current and $5.906 million long-term. The loan bears interest at 30-day U.S. LIBOR plus 5.41%, is secured by substantially all assets except intellectual property itself, and matures January 2021. The filing lists $8.207 million of scheduled term-loan payments, including fees, and total fixed contractual obligations of $11.279 million.

Material changes versus the prior comparable period

  • Q2 revenue and gross profit increased from 2016, while the operating loss widened by $1.063 million. Net loss narrowed, helped by higher warrant-revaluation gains and the absence of the 2016 preferred deemed dividend.
  • First-half operating loss increased by $2.562 million and net loss increased by $4.393 million. The revenue comparison is substantially affected by the $6.5 million prior-period deferred-revenue recognition; management also cited increased commercialization, clinical-research and product-development spending.
  • In May, the company reduced its workforce by approximately 27 employees and recorded $0.665 million in restructuring expense. The plan was completed by the end of Q2.
  • April’s registered direct offering generated approximately $10.9 million net, issuing 3.732 million common shares and warrants for 1.866 million shares. Common shares issued and outstanding rose to 25.789 million from 21.894 million at December 31, 2016.

Outlook, risks, contingencies and unusual items

  • Going concern: Management stated that existing cash was insufficient for operations for the 12 months after the financial statements’ issuance, raising substantial doubt about the company’s ability to continue as a going concern. It estimated resources could cover obligations into Q1 2018 under assumptions including modest revenue growth and lower costs after restructuring.
  • Proposed financing: In July, the board approved a proposed rights offering of up to $34 million gross at $1 per share, with a stated backstop commitment for unsubscribed shares subject to a 40% ownership cap. Management said proceeds, if obtained as expected in Q3, would provide sufficient cash for the following 12 months. Completion and proceeds were not assured.
  • In August, the lender suspended the minimum-liquidity covenant through September 16, 2017, in anticipation of the proposed financing. Before suspension, the required unrestricted cash level was $7.518 million; the company reported covenant compliance at June 30 and estimated effective unrestricted cash of $3.183 million after the restriction.
  • Additional financing may dilute existing shareholders. The filing says funding may not be available on acceptable terms or at all; absent financing, Ekso may need further expense reductions or to curtail operations.
  • On August 4, the company agreed, subject to conditions and holders exercising basic subscription rights, to repurchase the April 2017 warrants for $1.23 per share when the rights offering closes. The company also agreed to amend related purchase terms.
  • Other risks cited include medical-device regulatory approval, clinical-trial outcomes and timing, customer adoption and reimbursement, competition, long and variable sales cycles, intellectual-property protection, foreign-exchange exposure and ability to retain key employees. Management reported no material adverse effect expected from ordinary-course legal matters.
  • No specific revenue or earnings guidance was provided. Management described ongoing clinical studies, including a company-sponsored spinal-cord-injury study planned to enroll approximately 160 people, and said it was pursuing medical and industrial commercialization.

Important facts for investors to verify

  • Whether the proposed rights offering closed, how much capital it raised, and the resulting share dilution and ownership concentration.
  • Whether the warrant repurchase and amendment transactions closed and their cash and dilution effects.
  • Cash burn after the restructuring, remaining covenant requirements, and the company’s ability to fund operations beyond Q1 2018.
  • Underlying device sales and gross margins, separating current-period performance from the unusual 2016 deferred-revenue recognition.
  • Progress, results and regulatory implications of clinical studies, and whether sales and adoption meet management’s expectations.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.